Edwards Lifesciences
Edwards Lifesciences Corp
NYSE: EW. Canonical company identity and public leadership record.
US
- Alpha ID
- alpha:company:d86a8f77-509d-44fb-bed0-dc12f5f424c6
- SEC CIK
- 0001099800
- Website
- www.edwards.com Open
- Record version
- vpublic-1:ro-d751713988987e9331980363e24189ce, published Oct 16, 2026
- Newest evidence
- May 3, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Bernard ZovighianChief Executive Officer and Director
- Chair
- David T. Feinberg
- Independent
- 8 / 99 directors published
- Published claims
- 335 distinct sources
- Evidence records
- 100 pinned
- Source conflicts
- 0None open
Built from 5 distinct sources and 10 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
DIRECTOR APPOINTED
David T. Feinberg seat on Edwards Lifesciences, effective 2024-01-01.
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Senior Vice President, Corporate Controller | Amy E. Dahl | Not captured | unknown | Source reportedE4 |
| Chief Executive Officer and Director | Bernard Zovighian | Not captured | unknown | Source reportedE5 |
| Corporate Vice President, Transcatheter Aortic Valve Replacement (TAVR) | Daniel J. Lippis | Not captured | unknown | Source reportedE6 |
| Corporate Vice President, Strategy Corporate Development | Donald E. Bobo, Jr. | Not captured | unknown | Source reportedE7 |
| Corporate Vice President, Chief Financial Officer | Scott B. Ullem | Not captured | unknown | Source reportedE8 |
Board of directors
Evidence9 directors published. 8 of 9 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Bernard Zovighian | Not independent | 2023 | None published | Source reportedE3 |
| David T. Feinberg | IndependentChair | 2024 | Audit | Source reportedE3 |
| Kieran T. Gallahue | IndependentChair | 2015 | Audit | Source reportedE3 |
| Leslie C. Davis | Independent | 2024 | Compensation and Governance | Source reportedE3 |
| Leslie S. Heisz | Independent | 2016 | Audit, chairAudit · Chair | Source reportedE3 |
| Nicholas J. Valeriani | IndependentChair | 2014 | Compensation and Governance | Source reportedE3 |
| Paul A. LaViolette | Independent | 2020 | Compensation and Governance, chairCompensation and Governance · Chair | Source reportedE3 |
| Ramona Sequeira | Independent | 2020 | Audit | Source reportedE3 |
| Steven R. Loranger | IndependentChair | 2016 | Compensation and Governance | Source reportedE3 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | Leslie S. Heisz | Leslie S. Heisz, David T. Feinberg, Kieran T. Gallahue, Ramona Sequeira | Not described in the published record |
| Audit · Chair | Not published | Leslie S. Heisz | Not described in the published record |
| Compensation and Governance | Paul A. LaViolette | Paul A. LaViolette, Leslie C. Davis, Nicholas J. Valeriani, Steven R. Loranger | Not described in the published record |
| Compensation and Governance · Chair | Not published | Paul A. LaViolette | Not described in the published record |
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Financials and market context
Evidence| Index | Security | Status | Effective | Verification | Source |
|---|---|---|---|---|---|
| S&P 500 (S&P Dow Jones Indices) | NYSE: EW | current | Apr 1, 2011 | inferred | Slickcharts S&P 500 constituent table (public observation, not S&P DJI license) |
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Amy E. DahlSenior Vice President, Corporate Controllercompany:d86a8f77-509d-44fb-bed0-dc12f5f424c6:leadership_role:18
- Bernard ZovighianChief Executive Officer and Directorcompany:d86a8f77-509d-44fb-bed0-dc12f5f424c6:leadership_role:19, company:d86a8f77-509d-44fb-bed0-dc12f5f424c6:leadership_role:13
- Daniel J. LippisCorporate Vice President, Transcatheter Aortic Valve Replacement (TAVR)company:d86a8f77-509d-44fb-bed0-dc12f5f424c6:leadership_role:20
- Donald E. Bobo, Jr.Corporate Vice President, Strategy Corporate Developmentcompany:d86a8f77-509d-44fb-bed0-dc12f5f424c6:leadership_role:21
- Scott B. UllemCorporate Vice President, Chief Financial Officercompany:d86a8f77-509d-44fb-bed0-dc12f5f424c6:leadership_role:22
- David T. FeinbergMembercompany:d86a8f77-509d-44fb-bed0-dc12f5f424c6:leadership_role:9
- Kieran T. GallahueChaircompany:d86a8f77-509d-44fb-bed0-dc12f5f424c6:leadership_role:10
- Leslie C. DavisIndependent Directorcompany:d86a8f77-509d-44fb-bed0-dc12f5f424c6:leadership_role:14
- Leslie S. HeiszIndependent Directorcompany:d86a8f77-509d-44fb-bed0-dc12f5f424c6:leadership_role:15
- company:d86a8f77-509d-44fb-bed0-dc12f5f424c6:leadership_role:11
- Paul A. LaVioletteIndependent Directorcompany:d86a8f77-509d-44fb-bed0-dc12f5f424c6:leadership_role:16
- Ramona SequeiraIndependent Directorcompany:d86a8f77-509d-44fb-bed0-dc12f5f424c6:leadership_role:17
- Steven R. LorangerChaircompany:d86a8f77-509d-44fb-bed0-dc12f5f424c6:leadership_role:12
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 10 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 16, 2026. Cited by 6 Claims.
- E2Edwards Lifesciences Corp Form 10-K (filed 2026-02-25). SEC filing. Retrieved Aug 29, 2026. Cited by 2 Claims.
- E3sec proxy. Published Mar 26, 2026. Retrieved May 3, 2026. Cited by 9 Claims.
- E4EW executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E5EW executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E6EW executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E7EW executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E8EW executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E9board_seats. sp500-board-director-completeness-remediation-2026-05-15. Cited by 10 Claims.
- E10Slickcharts S&P 500 constituent table (public observation, not S&P DJI license). index provider. Retrieved Sep 2, 2026. Cited by 1 Claim.
What changed in version public-1:ro-d751713988987e9331980363e24189ce
vpublic-1:ro-d751713988987e9331980363e24189ce published Oct 16, 2026- David T. Feinberg seat on Edwards Lifesciences, effective 2024-01-01.
- David T. Feinberg chairs board Edwards Lifesciences, effective 2024-01-01.
- Leslie C. Davis seat on Edwards Lifesciences, effective 2024-01-01.
- David T. Feinberg member of Audit, effective 2024-01-01.
- Leslie C. Davis member of Compensation and Governance, effective 2024-01-01.
- Bernard Zovighian seat on Edwards Lifesciences, effective 2023-01-01.
- Paul A. LaViolette seat on Edwards Lifesciences, effective 2020-01-01.
- Ramona Sequeira seat on Edwards Lifesciences, effective 2020-01-01.
- Compensation and Governance · Chair committee of Edwards Lifesciences, effective 2020-01-01.
- Paul A. LaViolette member of Compensation and Governance · Chair, effective 2020-01-01.
- Leslie S. Heisz seat on Edwards Lifesciences, effective 2016-01-01.
- Steven R. Loranger seat on Edwards Lifesciences, effective 2016-01-01.
- Steven R. Loranger chairs board Edwards Lifesciences, effective 2016-01-01.
- Audit · Chair committee of Edwards Lifesciences, effective 2016-01-01.
- Leslie S. Heisz member of Audit · Chair, effective 2016-01-01.
- Kieran T. Gallahue seat on Edwards Lifesciences, effective 2015-01-01.
- Kieran T. Gallahue chairs board Edwards Lifesciences, effective 2015-01-01.
- Nicholas J. Valeriani seat on Edwards Lifesciences, effective 2014-01-01.
- Nicholas J. Valeriani chairs board Edwards Lifesciences, effective 2014-01-01.



